Clinical Trial Update: Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial sponsored by Abbott evaluated the safety and efficacy of ABT-510 in advanced renal cell carcinoma and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ABT-510 (ABT-510)

Snippet

Sponsor: Abbott | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED